Biotechnology

Carmell

Carmell released FY2024 Cumulative 3Q Earnings on November 14 (EST), with actual revenue of 32.84K USD and EPS of -0.4398

Carmell released FY2024 Q3 earnings on November 14 (EST) with actual revenue of 20.52 KUSD and EPS of -0.1376 USD

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Carmell(CTCX.US)